COLO B Coloplast A/S Class B

Coloplast A/S - Allocation of Share Options

Coloplast A/S - Allocation of Share Options

Report on transactions of executives and related parties in Coloplast shares and related securities

According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities.

The below transactions concern allocation of share options.

For further details, reference is made to Coloplast’s Remuneration Policy. The policy is available on the group website at this address:





  Details of the person discharging managerial responsibilities/person closely associated
a) Name Kristian Villumsen
2 Reason for the notification
a) Position/status President & CEO
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a) Name Coloplast A/S (CVR-no.: 69749917)
b) LEI 529900NN7SOJ5QG82X67
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Share options relating to B shares
Identification code ISIN: DK0060448595 (B shares)
b) Nature of the transaction Share option allocation
c) Price and volume Price Volume
0.00 49,153
d) Aggregated information  
-        Aggregated volume 49,153 share options
-        Price DKK 0.00
e) Date of the transaction 2024-02-09, 13:30 UTC
f) Place of the transaction Outside a trading venue



 

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Anders Lonning-Skovgaard
2 Reason for the notification
a) Position/status Executive Vice President & CFO
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a) Name Coloplast A/S (CVR-no.: 69749917)
b) LEI 529900NN7SOJ5QG82X67
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Share options relating to B shares
Identification code ISIN: DK0060448595 (B shares)
b) Nature of the transaction Share option allocation
c) Price and volume Price Volume
0.00 25,021
d) Aggregated information  
-        Aggregated volume 25,021 share options
-        Price DKK 0.00
e) Date of the transaction 2024-02-09, 13:30 UTC
f) Place of the transaction Outside a trading venue

 

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Paul Marcun
2 Reason for the notification
a) Position/status Executive Vice President, Growth
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a) Name Coloplast A/S (CVR-no.: 69749917)
b) LEI 529900NN7SOJ5QG82X67
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Share options relating to B shares
Identification code ISIN: DK0060448595 (B shares)
b) Nature of the transaction Share option allocation
c) Price and volume Price Volume
0.00 24,909
d) Aggregated information  
-        Aggregated volume 24,909 share options
-        Price DKK 0.00
e) Date of the transaction 2024-02-09, 13:30 UTC
f) Place of the transaction Outside a trading venue



 

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Allan Rasmussen
2 Reason for the notification
a) Position/status Executive Vice President, Global Operations
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a) Name Coloplast A/S (CVR-no.: 69749917)
b) LEI 529900NN7SOJ5QG82X67
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Share options relating to B shares
Identification code ISIN: DK0060448595 (B shares)
b) Nature of the transaction Share option allocation
c) Price and volume Price Volume
0.00 21,828
d) Aggregated information  
-        Aggregated volume 21,828 share options
-        Price DKK 0.00
e) Date of the transaction 2024-02-09, 13:30 UTC
f) Place of the transaction Outside a trading venue



 

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Nicolai Buhl Andersen
2 Reason for the notification
a) Position/status Executive Vice President, Innovation
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor
a) Name Coloplast A/S (CVR-no.: 69749917)
b) LEI 529900NN7SOJ5QG82X67
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Share options relating to B shares
Identification code ISIN: DK0060448595 (B shares)
b) Nature of the transaction Share option allocation
c) Price and volume Price Volume
0.00 20,615
d) Aggregated information  
-        Aggregated volume 20,615 share options
-        Price DKK 0.00
e) Date of the transaction 2024-02-09, 13:30 UTC
f) Place of the transaction Outside a trading venue



 



 

For further information, please contact

Investors and analysts

Anders Lonning-Skovgaard

Executive Vice President, CFO

Tel.

Aleksandra Dimovska

Senior Director, Investor Relations

Tel. /

Email:

Kristine Husted Munk

Senior Manager, Investor Relations

Tel. /

Email:

Press and media

Peter Mønster

Sr. Media Relations Manager

Tel.

Email:

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebaek

Denmark

Company reg. (CVR) no. 69749917

Website

 

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail.

Coloplast was founded on passion, ambition, and commitment. We were born from a nurse’s wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2024-02.



All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachment



EN
09/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

 PRESS RELEASE

Coloplast A/S - Invitation to Coloplast's Meet the Management event on...

Coloplast A/S - Invitation to Coloplast's Meet the Management event on 6 June 2024 (gentle reminder) The event will take place on Thursday, 6 June 2024 at Coloplast’s HeadquartersHoltedam 3, 3050 Humlebaek, Denmarkfrom 11.30 - 18.00 CEST (Central European Summer Time) Coloplast invites institutional investors, equity analysts and media to attend our 2024 Meet the Management event.The event will be held in person at our headquarters in Humlebaek, Denmark, with the option to join us virtually for the plenary session.The purpose of the event is to provide participants with the opportuni...

 PRESS RELEASE

Coloplast udvider Luja™-portefølje med nyt kateter til kvinder

Coloplast udvider Luja™-portefølje med nyt kateter til kvinder Engangskateteret gør det muligt for kvinder at tømme blæren i et frit flow1, hvilket nedsætter risikoen for urinvejsinfektioner2. Luja-platformen er med sin Micro-hole Zone Technology en ny generation af intermitterende engangskatetre til mennesker med behov for hjælp til at tømme deres blære. Efter en vellykket lancering af Luja til mandlige kateterbrugere lancerer Coloplast nu Luja til kvinder. ”Vi har modtaget rigtig god feedback for Luja til mænd i vores produktevalueringer. Næsten alle sundhedsprofessionelle anbefaler kat...

 PRESS RELEASE

Coloplast expands its Luja™ portfolio with next generation catheter fo...

Coloplast expands its Luja™ portfolio with next generation catheter for women The female intermittent catheter enables complete bladder emptying in one free flow1, aiming to reduce the risk of urinary tract infections2. Following the successful launch of Luja with Micro-hole Zone Technology, a next generation intermittent catheter for men, Coloplast is now launching Luja for women. “So far, we have received great feedback on Luja for men in our product evaluations. Nearly all healthcare professionals would recommend the male catheter to their patients3, and sev...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

Mixed emotions about Kerecis

Q2 EBIT was 3-4% below expectations. Kerecis goodwill writedown is a troublesome read. Too expensive, too-low EPS growth and too many questions: SELL.

Rune Majlund Dahl
  • Rune Majlund Dahl

Coloplast (Buy, TP: DKK1050.00) - Next up: ‘Meet the Management’

Q2 organic growth of 7.5% YOY was in line with our forecast and consensus, but the EBIT margin (b.s.i.) of 27.2% missed. Coloplast revised its 2023/24 reported revenue growth guidance to 10–11% (previously c11%) on FX, but kept its c8% organic growth and 27–28% EBIT margin (b.s.i.) guidance. At the upcoming ‘Meet the Management’ event, we expect an update on its clinical performance programme and a deep-dive into Kerecis. We reiterate our BUY and DKK1,050 target price.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch